<DOC>
	<DOCNO>NCT00436384</DOCNO>
	<brief_summary>Cytomegalovirus ( CMV ) common cause illness patient undergone transplant . Serious infection due CMV affect many part body include lung , gut , liver . Since transplant recipient risk CMV evidence infection CMV , give antiviral drug ( usually ganciclovir valganciclovir ) . Despite , chance CMV infection may cause problem future . The purpose study assess well patients'immune system respond CMV virus , future may possible predict patient high risk CMV .</brief_summary>
	<brief_title>Cell Mediated Immunity Prediction CMV Infection In Solid Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Male female patient fulfill follow criterion eligible inclusion . CMV D+/R liver , kidney heart recipient CMV R+ liver , kidney heart recipient receive thymoglobulin induction therapy . D+/R R+ lung transplant recipient . Able give write informed consent Are willing able comply protocol Age &gt; =18 year Patient unwilling unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>liver transplant</keyword>
	<keyword>lung transplant</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>heart transplant</keyword>
	<keyword>CMV CMI</keyword>
</DOC>